3 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
Primary, improvement of the quality of life.Secondary, reduction of pain and a decrease of the number of treatments by a breast oedema therapist.
Approved WMORecruiting
The objective of this study is to evaluate the 12-month outcomes of stenting with the Supera Peripheral Stent System (Abbott Vascular) versus endarterectomy in symptomatic (Rutherford 2-4) atherosclerotic lesions in the common femoral artery (CFA) (…